The mechanism and efficacy of GLP-1 receptor agonists in the treatment of Alzheimer's disease

被引：58
作者：
Du, Haiyang [1 ]
Meng, Xiaoyu [2 ,3 ]
Yao, Yu [1 ]
Xu, Jun [1 ]
机构：
[1] Harbin Med Univ, Affiliated Hosp 2, Dept Orthoped, Div Orthoped, Harbin, Peoples R China
[2] Huazhong Univ Sci & Technol, Tongji Hosp, Tongji Med Coll, Dept Internal Med,Div Endocrinol, Wuhan, Peoples R China
[3] Branch Natl Clin Res Ctr Metab Dis, Wuhan, Hubei, Peoples R China
来源：
FRONTIERS IN ENDOCRINOLOGY | 2022年 / 13卷
关键词：
Alzheimer's disease; GLP-1R agonists; cognitive function; amyloid beta; tau phosphorylation; GLUCAGON-LIKE PEPTIDE-1; AMYLOID-BETA PROTEIN; MODULATING TAU HYPERPHOSPHORYLATION; INTRACELLULAR CALCIUM HOMEOSTASIS; PROGENITOR-CELL PROLIFERATION; BRAIN INSULIN-RESISTANCE; LONG-TERM POTENTIATION; MOUSE MODEL; MEMORY IMPAIRMENT; SYNAPTIC PLASTICITY;
D O I：
10.3389/fendo.2022.1033479
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
Since type 2 diabetes mellitus (T2DM) is a risk factor for Alzheimer's disease (AD) and both have the same pathogenesis (e.g., insulin resistance), drugs used to treat T2DM have been gradually found to reduce the progression of AD in AD models. Of these drugs, glucagon-like peptide 1 receptor (GLP-1R) agonists are more effective and have fewer side effects. GLP-1R agonists have reducing neuroinflammation and oxidative stress, neurotrophic effects, decreasing A beta deposition and tau hyperphosphorylation in AD models, which may be a potential drug for the treatment of AD. However, this needs to be verified by further clinical trials. This study aims to summarize the current information on the mechanisms and effects of GLP-1R agonists in AD.
引用
收藏
页数：18
相关论文
共 245 条
[91]   TRUNCATED GLUCAGONLIKE PEPTIDE-I, AN INSULIN-RELEASING HORMONE FROM THE DISTAL GUT [J].
HOLST, JJ ;
ORSKOV, C ;
NIELSEN, OV ;
SCHWARTZ, TW .
FEBS LETTERS, 1987, 211 (02) :169-174
[92]   Liraglutide and a lipidized analog of prolactin-releasing peptide show neuroprotective effects in a mouse model of β-amyloid pathology [J].
Holubova, Martina ;
Hruba, Lucie ;
Popelova, Andrea ;
Bencze, Michal ;
Prazienkova, Veronika ;
Gengler, Simon ;
Kratochvilova, Helena ;
Haluzik, Martin ;
Zelezna, Blanka ;
Kunes, Jaroslav ;
Holscher, Christian ;
Maletinska, Lenka .
NEUROPHARMACOLOGY, 2019, 144 :377-387
[93]   Use of Glucagon-Like Peptide-1 Receptor Agonists in Patients With Type 2 Diabetes and Cardiovascular Disease A Review [J].
Honigberg, Michael C. ;
Chang, Lee-Shing ;
McGuire, Darren K. ;
Plutzky, Jorge ;
Aroda, Vanita R. ;
Vaduganathan, Muthiah .
JAMA CARDIOLOGY, 2020, 5 (10) :1182-1190
[94]   Drugs developed to treat diabetes, liraglutide and lixisenatide, cross the blood brain barrier and enhance neurogenesis [J].
Hunter, Kerry ;
Hoelscher, Christian .
BMC NEUROSCIENCE, 2012, 13
[95]   Apolipoprotein E and Alzheimer's disease: the influence of apolipoprotein E on amyloid-β and other amyloidogenic proteins [J].
Huynh, Tien-Phat V. ;
Davis, Albert A. ;
Ulrich, Jason D. ;
Holtzman, David M. .
JOURNAL OF LIPID RESEARCH, 2017, 58 (05) :824-836
[96]   Glucagon-Like Peptide-1 Protects Synaptic and Learning Functions From Neuroinflammation in Rodents [J].
Iwai, Takashi ;
Sawabe, Toshihiro ;
Tanimitsu, Kahori ;
Suzuki, Manabu ;
Sasaki-Hamada, Sachie ;
Oka, Jun-Ichiro .
JOURNAL OF NEUROSCIENCE RESEARCH, 2014, 92 (04) :446-454
[97]   Liraglutide in Type 2 Diabetes Mellitus: Clinical Pharmacokinetics and Pharmacodynamics [J].
Jacobsen, Lisbeth V. ;
Flint, Anne ;
Olsen, Anette K. ;
Ingwersen, Steen H. .
CLINICAL PHARMACOKINETICS, 2016, 55 (06) :657-672
[98]   Liraglutide Suppresses Tau Hyperphosphorylation, Amyloid Beta Accumulation through Regulating Neuronal Insulin Signaling and BACE-1 Activity [J].
Jantrapirom, Salinee ;
Nimlamool, Wutigri ;
Chattipakorn, Nipon ;
Chattipakorn, Siriporn ;
Temviriyanukul, Piya ;
Inthachat, Woorawee ;
Govitrapong, Piyarat ;
Potikanond, Saranyapin .
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2020, 21 (05)
[99]   Efficacy and safety of dulaglutide in the treatment of type 2 diabetes: a comprehensive review of the dulaglutide clinical data focusing on the AWARD phase 3 clinical trial program [J].
Jendle, Johan ;
Grunberger, George ;
Blevins, Thomas ;
Giorgino, Francesco ;
Hietpas, Ryan T. ;
Botros, Fady T. .
DIABETES-METABOLISM RESEARCH AND REVIEWS, 2016, 32 (08) :776-790
[100]   Exendin-4, a glucagon-like peptide 1 receptor agonist, protects against amyloid-β peptide-induced impairment of spatial learning and memory in rats [J].
Jia, Xiao-Tao ;
Ye-Tian ;
Yuan-Li ;
Zhang, Ge-Juan ;
Liu, Zhi-qin ;
Di, Zheng-Li ;
Ying, Xiao-Ping ;
Fang, Yan ;
Song, Er-fei ;
Qi, Jin-shun ;
Pan, Yan-Fang .
PHYSIOLOGY & BEHAVIOR, 2016, 159 :72-79
567891011121314